Tango Therapeutics Goes Public in $353M Deal

Posted by ISPE Boston
On April 22, 2021

Precision cancer medicine company Tango Therapeutics has entered into a definitive merger agreement with SPAC (special purpose acquisition company) BCTG Acquisition Corp. In addition to the approximately $167 million contributed by BCTG, a group of healthcare investors has committed to participate in the transaction through a common stock PIPE (or private investment in public equity) […]

Happy National Volunteer Week!

Posted by ISPE Boston
On April 21, 2021

Happy National Volunteer Week! Did you know there’s a whole week to celebrate amazing volunteers like you? National Volunteer Week takes place the third week in April each year and we couldn’t let this opportunity pass us by to celebrate our amazing ISPE volunteers! This year, our volunteers haven’t missed a beat due to COVID-19. […]

Broad Institute Launches $300M Initiative Linking AI and Life Sciences

Posted by ISPE Boston
On April 15, 2021

The Broad Institute of MIT and Harvard have launched the Eric and Wendy Schmidt Center, an initiative funded by a $150 million endowment gift from the Schmidts that will catalyze a new scientific discipline at the intersection of biology and machine learning. Based in Cambridge at the Broad Institute, the center will bring together a global […]

Repertoire Immune Medicines Secures $189M Financing

Posted by ISPE Boston
On April 15, 2021

Cambridge biotech Repertoire Immune Medicines has completed a $189 million Series B financing. The company is focused on decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases. Proceeds from this financing will support further expansion of the company’s proprietary DECODE discovery platform, accelerate its clinical […]

Sage Therapeutics and Biogen Announce Positive Phase 2 Results

Posted by ISPE Boston
On April 15, 2021

Sage Therapeutics and Biogen have reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET). The study achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo. “We are encouraged by the positive results of the KINETIC Study, which indicate that […]

EDEI Panelists Tie Diversity to Business Success

Posted by Eric Felz
On April 8, 2021

On February 24, the Chapter’s newly formed Ethnocultural Diversity, Equity, and Inclusion (EDEI) Committee held its kick-off event and panel discussion via Zoom webinar. This panel discussion covered how companies should be fostering a more diverse workforce and why diversity within a company makes good business sense. Our panel of speakers included: Dr. John Armendariz, […]

J&J Takes Over COVID Vaccine Manufacture at Emergent

Posted by ISPE Boston
On April 8, 2021

Johnson & Johnson has announced that it is assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at contract manufacturer Emergent BioSolutions Maryland facility. Specifically, J&J is adding dedicated leaders for operations and quality, and significantly increasing the number of manufacturing, quality and technical operations personnel to work with the company’s […]

Aveo Oncology Wins FDA Approval for Kidney Cancer Drug

Posted by ISPE Boston
On April 8, 2021

Aveo Oncology has announced FDA approval for Fotivda (tivozanib) for the treatment of adults with renal cell carcinoma (RCC) who meet certain treatment guidelines. Fotivda is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and was approved in August 2017 in the European Union and other EUSA countries. According to the American Cancer Society, renal cell […]

ElevateBio Scales Business Model with $525M Financing Round

Posted by ISPE Boston
On April 8, 2021

ElevateBio has raised $525 million in a Series C financing. According to its website, the company has created a business model addressing the most pressing challenges in the field of cell and gene therapy. Its suite of technologies includes gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering. With this financing, ElevateBio […]

Chapter Member Anniversaries: April 2021

Posted by ISPE Boston
On April 5, 2021

Please congratulate the following members celebrating milestone anniversaries in April 2021. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Michael S. Cheney, Biogen Idec Donald Cole, Hart Passivation Services, Inc. Daniel D. Crosby, Bristol Myers Squibb James P. Grunwald, DPS Group Paul F. Herbert, Elektrofi Inc Donna […]

Page 49 of 117«‹47 484950 51 ›»